Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry to monitor safety of LOBO device in bleeding emergencies

NCT ID NCT07525518

Knowledge-focused Sponsor: Okami Medical, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This registry will follow 500 adults who receive the LOBO Vascular Occlusion System, a device used to block blood vessels in cases of arterial bleeding or other conditions. The goal is to see how safe and effective the device is in everyday medical practice. Participants are enrolled after treatment, and the study will track device-related complications and how well the device stops bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LOBO Vascular Occlusion System (a device used to block blood vessels)
What this could lead to
If successful, this registry will provide real-world data on how well the LOBO device works and its safety, helping doctors make better treatment decisions.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be limited by patient selection and lack of a comparison group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a clinical condition treated with LOBO Vascular Occlusion System

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient or their legally authorized representative is willing and able to provide informed consent per local requirements * Has or will receive treatment with an eligible Okami Medical device * Age ≥ 18 years Exclusion Criteria: * Is or will be inaccessible for registry follow-up * Meets exclusion criteria required by local requirements * Current or planned participation in a drug or device study that would interfere with participation in this registry or confound the results of this registry in the opinion of the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial bleed are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arteriovenous hemangioma/malformation Hemorrhage Pulmonary Arteriovenous Fistulas

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial bleed Embolization Hemorrhage Pulmonary arteriovenous malformation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charlotte Radiology

    Charlotte, North Carolina, 28202, United States

  • UMASS Chan Medical School

    Worcester, Massachusetts, 01655, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.